The result is a paradox. Even before the HTA Review is formally concluded, announced, and implemented, the environment it was meant to reform has already worsened. Expectations that the review would stabilise or improve conditions now need to be recalibrated. The baseline has moved, and not in a favourable direction. …
To what extent does the system even see itself as bound by external review?
March 25, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
A 'Stronger PBS' makes way for 'We are now in a fight to save the PBS'
June 25, 2026 - - Latest News -
Key report findings - 'Cost of Inaction - Australian voices on equitable access to diabetes technology'
June 25, 2026 - - BioPharma -
New Zealand last among peers for publicly funded modern medicines
June 25, 2026 - - Latest News -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News -
Early real world data shows improvement in treatment resistant depression
June 24, 2026 - - Latest News -
FDA backs AFT’s injectable iron into Phase 3 study as company targets global scale
June 24, 2026 - - Latest News -
Neurizon presents new mechanistic evidence that NUZ-001 restores proteostasis and supports ALS resilience
June 24, 2026 - - Australian Biotech